Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ASTX660 is an orally bioavailable dual antagonist of cIAP and XIAP.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 76.00 | |
5 mg | In stock | $ 147.00 | |
10 mg | In stock | $ 228.00 | |
25 mg | In stock | $ 455.00 | |
50 mg | In stock | $ 672.00 | |
100 mg | In stock | $ 956.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 175.00 |
Description | ASTX660 is an orally bioavailable dual antagonist of cIAP and XIAP. |
In vitro | Twenty-one triple-negative breast cancer (TNBC) cell lines are treated with ASTX660 in vitro and it is found that 43% are sensitive to ASTX660. |
In vivo | ASTX660 (daily oral treatment) inhibits tumor growth moderately but not a regression in HCC1806 xenografts in mice. |
Molecular Weight | 539.68 |
Formula | C30H42FN5O3 |
CAS No. | 1799328-86-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 47 mg/mL(87.09 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ASTX660 1799328-86-1 Apoptosis IAP ASTX-660 Inhibitor inhibit ASTX 660 inhibitor